Background: The prognosis of patients diagnosed with locally advanced and metastatic gastric and esophago-gastric junction cancer is critical. The optimal choice of systemic therapy is essential to optimize survival outcomes. Methods: A comprehensive literature review via PubMed and analysis of major oncology congresses (European Society for Medical Oncology and American Society of Clinical Oncology websites) were conducted to ascertain the current status and latest developments in the systemic treatment of patients with localized or advanced gastric and esophago-gastric junction adenocarcinoma. Results: While neoadjuvant and perioperative chemotherapy for localized tumor stages is the preferred approach in the Western Hemisphere, adjuvant chemotherapy remains the preferred course of action in East Asia. The administration of chemotherapy, typically in the form of combinations comprising platinum and fluoropyrimidine compounds in combination with docetaxel, represents a standard of care. Investigations are underway into the potential of immunotherapy and other biologically targeted agents in the perioperative setting. To select the most appropriate therapy for advanced gastric cancer, including adenocarcinoma of the esophago-gastric junction, it is essential to determine biomarkers such as HER2 expression, PD-L1 combined positive score (CPS) (combined positive score), Claudin 18.2, and microsatellite instability (MSI). In the present clinical context, the standard first-line therapy is a combination of fluoropyrimidine and a platinum derivative. The selection of chemotherapy in combination with antibodies is contingent upon the specific biomarker under consideration. Conclusions: This article reviews the current state of the art based on recent clinical trial results and provides an outlook on the future of systemic therapy.
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- MeSH
- gastroezofageální junkce MeSH
- lidé MeSH
- nádory jícnu * farmakoterapie genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
- práce podpořená grantem MeSH
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. The European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Faculty aims to increase the skills of medical oncologists and other disciplines involved in treating GI malignancies. We aimed to increase the survival chances for patients with GI cancers, augment their quality of life and enable successful return to normal social and professional life during the period of survivorship. ESMO also aims to decrease the economic burden of GI cancer in our societies and national healthcare systems. Therefore, the ESMO Gastrointestinal Cancer Faculty initiated a consensus process based on the Delphi method to identify the most important educational needs of physicians who are concerned with GI malignancies. This paper summarises the process and its results and outlines the mission of ESMO in education.
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- MeSH
- antigeny CD274 antagonisté a inhibitory MeSH
- cílená molekulární terapie MeSH
- lidé MeSH
- nádory jícnu * farmakoterapie imunologie patologie MeSH
- oprava chybného párování bází DNA účinky léků MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- protoonkogenní proteiny c-met antagonisté a inhibitory MeSH
- receptor erbB-2 antagonisté a inhibitory MeSH
- receptory fibroblastových růstových faktorů antagonisté a inhibitory MeSH
- receptory vaskulárního endoteliálního růstového faktoru antagonisté a inhibitory MeSH
- signální transdukce účinky léků MeSH
- transkripční faktor STAT3 antagonisté a inhibitory MeSH
- trastuzumab terapeutické užití MeSH
- Check Tag
- lidé MeSH
Pneumologie ; Vol. 4
1 CD-ROM
- MeSH
- CD-ROM MeSH
- nemoci dýchací soustavy MeSH
- Publikační typ
- kazuistiky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- pneumologie a ftizeologie
- NLK Publikační typ
- CD-ROM
- software
